Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q2 2024 · 10-Q
Revenue$0.00$0.00— vs Q2 2023 Net Income-$353.58K-$353.58KN/M vs Q2 2023 EPS Diluted$0.00$0.00— vs Q2 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
-$353,583
N/M
Operating Cash Flowderived$188N/M ended Jul 31, 2023 · filed Jan 23, 2026 · 907 d after period end